Witryna6 sty 2024 · Background The programmed cell death 1 (PD-1) inhibitor pembrolizumab is a promising agent for treatment of several different malignancies, but as with all immunotherapy there is a potential risk of immune-related adverse events. Adrenocorticotropic hormone (ACTH) deficiency and hypophysitis have been reported … WitrynaA 68-year-old woman was diagnosed with metastatic sarcomatoid non–small cell lung cancer. She was initiated on pembrolizumab therapy and achieved partial remission. Four months later, she was found to have orthostatic hypotension, with blood pressure of 90/50 mm Hg sitting and serum sodium concentration of 123 mmol/L. Serum …
NOT ALL CANCER RELATED HYPONATREMIA IS SIADH
WitrynaHyponatremia is decrease in serum sodium concentration < 136 mEq/L ( < 136 mmol/L) caused by an excess of water relative to solute. Common causes include diuretic use, diarrhea, heart failure, liver disease, renal disease, and the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Clinical manifestations are primarily … WitrynaThis might have been precipitated by immunotherapy. Hyponatremia was likely exacerbated by hypovolemia due to nausea and vomiting. The clinical picture was … software portal otu
Keytruda (pembrolizumab): Side effects, uses, cost, …
WitrynaNivolumab can cause primary adrenal insufficiency.Not all cases of hyponatraemia in patients with malignancy are due to SIADH.Any patient on a checkpoint inhibitor … Witryna6 mar 2024 · Introduction. Syndrome of inappropriate antidiuretic hormone ADH release (SIADH) is a condition defined by the unsuppressed release of antidiuretic hormone (ADH) from the … Witryna8 kwi 2024 · All 82 patients underwent the first-line immunotherapy (steroids, intravenous immunoglobulins, and plasma exchange alone or combined), and 52 patients had symptom improvement within 4 weeks of treatment. Second-line immunotherapy (immunosuppressants) was added to 11 patients and 4 patients had a good … software portal app